BIOCHEMICAL AND HISTOCHEMICAL EXAMINATIONS ON LIPJD-BINDING PROTEINS (LBP), PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) AND RETINOL RECEPTORS (RXR) IN KIDNEY.
BIOCHEMICAL AND HISTOCHEMICAL EXAMINATIONS ON LIPJD-BINDING PROTEINS (LBP), PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) AND RETINOL RECEPTORS (RXR) IN KIDNEY.
批准号:
12671034
负责人:
KIMURA Hideki
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
1. 人正常与病变肾脏中flbp和PPARs表达的研究。(1)在正常人肾脏中,肝型(L-)脂肪酸结合蛋白(FABP)和心脏型FABP分别主要定位于肾小管上皮细胞(RTEC)的近端和远端细胞质中。PPAR-α主要存在于近端RTEC细胞质中,PPAR-γ主要存在于远端RTEC细胞质和收集管中。(2)重度缺氧的移植肾,部分近端rtec细胞质中L-FABP和PPAR-α表达升高。在间质性肾炎中,一些rtec近端可见L-FABP和PPAR-α的核染色,提示L-FABP与PPAR-α的相互作用。纯化的L-FABP含有内源性长链脂肪酸,可作为PPAR-α的配体和刺激剂。在间质性肾炎中,PPAR-α在浸润性嗜酸性细胞中表达,而在巨噬细胞中不表达。膜性肾病的核染色显示PPAR-α含量高于正常肾。人培养肾小管近端上皮细胞中lbp和PPARs表达的研究。(1)间接免疫荧光法和免疫印迹法显示L-FABP和PPAR-α在培养的人肾近端小管上皮细胞中表达。PAI-1在培养细胞中也有表达。(2)人近端肾小管细胞在含多种生长因子和生物活性分子的培养基中培养后,在浓度为250 ~ 600 ng/mL的培养基中检测到PAI-1抗原。在基础培养基中加入氢化可的松和肾上腺素可使培养细胞条件培养基中PAI- 1的浓度升高。缺氧似乎进一步诱导了生长培养基中培养细胞PAI-1的表达。临床变量与晚期肾脏疾病及血管疾病的关系分析。在高HDL-C血液透析患者中,胆固醇酯转移蛋白(CETP)是预防血管疾病的保护因子。亚甲基四氢叶酸还原酶(MTHFR)基因中一种常见的C677T突变与血清同型半胱氨酸水平升高有关,从而导致内皮细胞氧化应激。纯合突变体(TT基因型)在诱导血液透析时更年轻,透析持续时间更短,这表明高同型半胱氨酸血症可能与开始透析后肾损害的加速进展和死亡率有关。在糖尿病患者中,严重蛋白尿超过1000 mg/gCr的患者尿液中PAI-1浓度高于微量白蛋白尿患者,而血浆PAI-1水平在糖尿病肾病的进展过程中保持不变。尿PAI-1水平与尿NAG和糖水平呈正相关。少
英文摘要
1. Investigation on the expression ofLBPs and PPARs in normal and diseased human kidneys.(1) In normal human kidney, liver type (L-) fatty acid-binding protein (FABP) and heart-type FABP were predominantly localized in cytoplasm of proximal and distal renal tubular epithelial cells (RTEC), respectively. PPAR-α was mainly present in cytoplasm of proximal RTEC and PPAR-γ was present in cytoplasm of distal RTEC and collecting ducts.(2) As for transplanted kidneys suffering from severe hypoxia, the expressions of L-FABP and PPAR-α were increased in cytoplasm of some proximal RTECs. In interstitial nephritis, nuclear stainings for L-FABP and PPAR-α were found in some proximal RTECs, suggesting the interaction between L-FABP and PPAR-α. Purified L-FABP contained endogenously long-chain fatty acids which can serve as ligands, stimulators for PPAR-α. In interstitial nephritis, PPAR-α was expressed in infiltrating eosinophils but not macrophages. In membranous nephropathy, nuclear staining for … More PPAR-α was more frequent than normal kidney.2. Investigation on the expression of LBPs and PPARs in human cultured proximal renal tubular epithelial cells.(1) Indirect immunofluorescence method and immunoblotting revealed that L-FABP and PPAR-α were expressed in human cultured proximal renal tubular epithelial cells. PAI-1 was also expressed in the cultured cells.(2) PAI-1 antigen was detected in the medium of human cultured proximal renal tubular cells at a concentration of 250-600 ng/mL after the cells were cultured in the medium including several growth factors and bioactive molecules. Addition of hydrocortisone and epinephrine to the basic medium increased the concentration of PAI- 1 in the conditioned medium of the cultured cells. Hypoxia appeared to induce further the expression of PAI-1 in the cells cultured in the growth medium.3. Analysis of relationships between clinical variables and advanced renal disease and vascular disease.In hemodialysis patients with high HDL-C status, cholesteryl ester transfer protein (CETP) was a protective factor against vascular disease. A common C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene was associated with increased serum levels of homocysteine which causes oxidative stress to endothelial cells. The homozygous mutants (TT genotype) were younger at the induction of hemodialysis and had a shorter duration of dialysis, suggesting that hyperhomocysteinemia may be related to accelerated progression of renal damage and mortality after initiation of dialysis. Among diabetic patients, PAI-1 concentrations in urine were higher in those with severe proteinuria over 1000 mg/gCr than those with microalbuminuria, while plasma PAI-1 levels were unchanged during progression of diabetic nephropathy. Urinary PAI-1 levels were positively associated with urinary NAG and sugar levels. Less
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Tsukahara H.: "Methylenetetrahydrofolate reductase polymorphismin Kawasaki disease"Pediat. Int.. 742. 236-240 (2001)
Tsukahara H.:“川崎病中的亚甲基四氢叶酸还原酶多态性”Pediat。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kimura H: "Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients"Am. J. Kidney Dis.. (2001)
Kimura H:“胆固醇酯转移蛋白作为血液透析患者血管疾病的保护因子”Am。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kimura H: "AC677T mutation in the methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients"Am. J. Kidney Dis.. 36. 925-933 (2000)
Kimura H:“亚甲基四氢叶酸还原酶基因中的 AC677T 突变会改变透析患者的血清半胱氨酸”Am。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tsukahara H: "Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease"Pediat. Int.. 42. 236-240 (2000)
Tsukahara H:“川崎病中的亚甲基四氢叶酸还原酶多态性”Pediat。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kimura H.: "A C677T mutation in the methylenetetrahydrofolatereductase gene modifies serum cysteine in dialysis patients"Am. J. Kidney Dis.. 36. 925-933 (2000)
Kimura H.:“亚甲基四氢叶酸还原酶基因中的 C677T 突变会改变透析患者的血清半胱氨酸”Am。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 23 条
Analysis of anti-fibrotic effects of lipid-responsible transcription factors and a search for new therapeutic agents -with special attention to hypoxic insults-
-
批准号:24591193
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2012
-
负责人:KIMURA Hideki
-
依托单位:
Investigation for anti-renal fibrotic effects of lipid-binding proteins and lipid-activated nuclear receptors and search for new therapeutic reagents
-
批准号:21591024
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2009
-
负责人:KIMURA Hideki
-
依托单位:
Diachronic Changes and Panchronic Universal Properties of Constructions and Grammatical Categories in Chinese-a Reconstruction of Historical Chinese Grammar
-
批准号:19320057
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.9万
-
财政年份:2007
-
负责人:KIMURA Hideki
-
依托单位:
Analysis for anti-inflammatory and anti-fibrotic actions of lipid transfer proteins and lipid-activated transcription factors in the progressive renal injury
-
批准号:19590944
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2007
-
负责人:KIMURA Hideki
-
依托单位:
Investigation on anti-inflammatory effects of lipid-binding proteins and lipophilic transcriptional factors in progression of renal injury.
-
批准号:17590823
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2005
-
负责人:KIMURA Hideki
-
依托单位:
Diachronic Changes and Panchronic Universal Properties of Constructions and Grammatical Categories in Chinese-a Reconstruction of Historical Chinese Grammar
-
批准号:16320049
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.98万
-
财政年份:2004
-
负责人:KIMURA Hideki
-
依托单位:
Investigation on anti-inflammatory effects of lipid-binding proteins in progression of renal injury.
-
批准号:14571021
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2002
-
负责人:KIMURA Hideki
-
依托单位:
Research onChinese Construction Categories and Event Perception
-
批准号:13610533
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2001
-
负责人:KIMURA Hideki
-
依托单位:
BIOCHEMICAL AND HISTOCHEMICAL EXAMINATIONS ON LIPID-BINDING PROTEINS IN RAT AND HUMAN KIDNEY
-
批准号:09671159
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.73万
-
财政年份:1997
-
负责人:KIMURA Hideki
-
依托单位:
Immunotherapy of lung cancer using biotechnological methods.
-
批准号:01480338
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.16万
-
财政年份:1989
-
负责人:KIMURA Hideki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
稳定期COPD中医证型的脂代谢紊乱特征及PPARγ/CPT1A调控机制及临床研究
-
批准号:JCZRLH202601649
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于“郁痰”理论探讨海藻消瘤胶囊调控ERα-PPARγ轴抑制PTC细胞代谢失衡的作用机制
-
批准号:JCZRLH202601582
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
IPA靶向FABP4/PPARγ信号通路改善肥胖相关性肾小球疾病
-
批准号:2026JJ81107
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:贺超
-
依托单位:
M2巨噬细胞外泌体通过MEG3/PPARγ/Nrf2轴介导铁死亡抑制子痫前期进展的作用及机制研究
-
批准号:2026JJ50641
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:喻玲
-
依托单位:
基于PPARα—肠道菌群—代谢物探讨非诺贝特改善高尿酸血症性肾病的作用及机制研究
-
批准号:2026JJ60065
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李璐
-
依托单位:
GPER激活通过PPARγ抑制小胶质细胞脂滴累积缓解绝经期抑郁
-
批准号:2026JJ82277
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈亮
-
依托单位:
BMP4 p.H251Y突变抑制巨噬细胞PPARγ-LXRα-ABCA1/G1通路导致青年冠心病的机制研究
-
批准号:JCZRLH202601083
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
涤痰益智汤通过PPARα/PGC-1α/PDK4信号轴重塑线粒体能量代谢稳态治疗血管性痴呆的机制研究
-
批准号:JCZRLH202601058
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
蒲公英甾醇通过 PPAR 通路调控巨噬细胞 M2极化减轻肝细胞凋亡抑制高毒力肺炎克雷伯菌致肝脓肿形成的机制研究
-
批准号:ZCLMS26H2002
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:孙瑶
-
依托单位:
基于PPARγ/PGC1α信号通路探究Alox15在阿霉素诱导心肌病中的作用与潜在机制
-
批准号:JCZRQNB202600846
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: